Pharmigene’s Genetic Test for Carbamazepine Response Now Standard in 50 Taiwan Hospitals | GenomeWeb

By Molika Ashford

Pharmigene said last week that 50 hospitals in Taiwan will now administer its genetic test to predict adverse events in patients being considered for treatment with the anti-seizure drug carbamazepine.

Under the partnership, the hospitals will use Pharmigene's test for the human leukocyte antigen gene variant HLA-B*1502 in order to reduce incidence of carbamazepine's severe, sometimes life-threatening side effects: Stevens-Johnson syndrome and toxic epidermal necrolysis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.